TIMP1 Mediates Astrocyte-Dependent Local Immunosuppression in Brain Metastasis Acting on Infiltrating CD8+ T Cells

Area of Science:

• Neuro-oncology
• Immunology
• Cancer Biology

Background:

• Immunotherapies show promise for asymptomatic brain metastases but fail in symptomatic cases.
• The reasons for immunotherapy resistance in symptomatic brain metastases are not fully understood.
• Astrocytes play a role in the tumor microenvironment, but their specific function in brain metastasis immunity is unclear.

Purpose of the Study:

• To investigate the heterogeneity of astrocytes in brain metastases.
• To identify astrocyte populations that impede anti-tumor immune responses.
• To explore novel therapeutic strategies for symptomatic brain metastases.

Main Methods:

• Single-cell RNA sequencing to analyze astrocyte heterogeneity.
• In vivo studies using mouse and human brain metastasis models.
• Genetic and pharmacologic interventions to modulate astrocyte function and immune responses.

Main Results:

• A specific population of pSTAT3+ astrocytes secretes tissue inhibitor of metalloproteinase-1 (TIMP1).
• TIMP1 from these astrocytes suppresses the anti-tumor activity of CD63+ CD8+ T cells.
• Combined inhibition of astrocyte-mediated immunosuppression and immune checkpoint blockade shows therapeutic potential in preclinical models.
• TIMP1 in liquid biopsies can serve as a biomarker for patient selection.

Conclusions:

• Astrocytes exhibit protumoral activity in brain metastases by secreting TIMP1, which inhibits T cell function.
• Targeting astrocyte-mediated immunosuppression alongside immune checkpoint inhibitors offers a potential treatment for symptomatic brain metastases.
• TIMP1 is a promising biomarker for identifying patients who may benefit from this combination therapy.